Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$110.28 USD

110.28
9,182,186

0.00 (0.00%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $113.75 +3.47 (3.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Incyte (INCY) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Incyte's (INCY) fourth-quarter 2022 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.

Zacks Equity Research

Why Gilead (GILD) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Will Eylea and Dupixent Fuel Regeneron's (REGN) Q4 Earnings?

by Zacks Equity Research

Regeneron's (REGN) fourth-quarter earnings are likely to have gotten a boost from the solid performances of Eylea and Dupixent.

Zacks Equity Research

Should iShares Select Dividend ETF (DVY) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for DVY

Zacks Equity Research

Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Should Franklin U.S. Low Volatility High Dividend Index ETF (LVHD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for LVHD

Zacks Equity Research

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed the most recent trading day at $83.62, moving -0.54% from the previous trading session.

Zacks Equity Research

Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed the most recent trading day at $84.02, moving +0.95% from the previous trading session.

Zacks Equity Research

Gilead (GILD) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2022 results.

Zacks Equity Research

GILD or GMAB: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GILD vs. GMAB: Which Stock Is the Better Value Option?

Zacks Equity Research

Gilead (GILD) Gains 21% in a Year: Will the Trend Continue?

by Zacks Equity Research

Biotech giant Gilead (GILD) gains 21% in the past 12 months as its core HIV business maintains momentum despite volatility.

Zacks Equity Research

Should You Invest in the VanEck Biotech ETF (BBH)?

by Zacks Equity Research

Sector ETF report for BBH

Zacks Equity Research

Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $85.41 in the latest trading session, marking a -1% move from the prior day.

Zacks Equity Research

Should SPDR Russell 1000 Yield Focus ETF (ONEY) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ONEY

Zacks Equity Research

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Zacks Equity Research

Is iShares Select Dividend ETF (DVY) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for DVY

Zacks Equity Research

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Gilead Sciences (GILD) closed at $87.19, marking a +0.06% move from the previous day.

Zacks Equity Research

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB

Zacks Equity Research

Is Franklin U.S. Low Volatility High Dividend Index ETF (LVHD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for LVHD

Zacks Equity Research

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $85.50 in the latest trading session, marking a +0.13% move from the prior day.

Zacks Equity Research

Gilead's (GILD) Application for Trodelvy Gets EMA Validation

by Zacks Equity Research

Gilead Sciences (GILD) gets EMA validation for its application for breast cancer drug Trodelvy in the European Union.

Zacks Equity Research

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Gilead Sciences (GILD) closed at $85.26, marking a +0.82% move from the previous day.

Zacks Equity Research

Biotech Stock Roundup: GILD's HIV Drug Approval, PRQR Surges on LLY Deal & More

by Zacks Equity Research

Updates from Gilead Sciences (GILD) and ProQR (PRQR) are the key highlights from the biotech sector during the past week.

Andrew Rocco headshot

Biotech: 3 Profitable Bios Worth Owning

by Andrew Rocco

The biotechnology space can be a difficult area to generate profits. Drugs take years to develop and often fail FDA approval. Today we will look at three top biotech stocks that are very profitable and have attractive future prospects.